Skip to main content
    E

    Edgewise Therapeutics Inc (EWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $42.04
    -1.64 (-3.75%)

    Market Cap: $5.03B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Edgewise Therapeutics Inc (EWTX) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Edgewise Therapeutics (EWTX) has a market cap of $5.03B and an enterprise value of $4.96B. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 3.20% from a year earlier.

    Total Valuation

    Enterprise value is 1.37% below the market cap, as cash exceeds debt.

    Market Cap$5.03B
    Enterprise Value$4.96B
    Latest price (Nov 17, 2026)$42.04

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 1.12% in the quarter ended Sep 30, 2026 and grew 7.73% a year over 2 years.

    Shares Outstanding108.87M
    Shares Change (YoY)+3.20%
    Shares Change (QoQ)+1.12%
    Share Count Growth (2Y CAGR)+7.73%

    Valuation Ratios

    Forward P/E63.1x
    P/B Ratio2.8x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 4.0x EBITDA.

    EV / Earnings4.9x
    EV / EBITDA4.0x

    Price Statistics

    The stock is up 84.79% over 52 weeks and trades 1.77% above its 50-day average.

    Beta (1Y)1.12
    52-Week Change+84.79%
    1-Month Change+10.87%
    3-Month Change-9.47%
    6-Month Change+33.76%
    5-Year Change+135.76%
    Total Return (1Y)+84.79%
    Total Return (3Y CAGR)+87.35%
    Total Return (5Y CAGR)+14.96%
    Return vs SPY (1Y)+78.15%
    Max Drawdown (1Y)-24.96%
    Max Drawdown (3Y)-68.81%
    Sharpe Ratio (1Y)0.92
    Correlation with SPY (1Y)0.22
    50-Day Average$41.31
    200-Day Average$37.15
    52-Week Range$19.76 to $48.78
    RSI (14 Days)49.9
    Average Volume (20 Days)1.68M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 12.30x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio12.30x
    Quick Ratio12.30x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is 61.84% over the last 12 months, against a 5-year average of -25.56%.

    Return on Equity (ROE)61.84%
    Return on Assets (ROA)56.72%
    ROE (5Y Average)-25.56%
    ROA (5Y Average)-24.15%
    ROIC (5Y Average)-28.95%

    Taxes

    Income tax took 13.33% of pretax income over the last 12 months.

    Income Tax (TTM)$155.33M
    Effective Tax Rate13.33%

    Scores

    EWTX has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Operating Income-$218.18M
    Pretax Income$1.16B
    Net Income$1.01B
    Reported EPS (TTM)-$0.62

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 91.57% of the $1.78B in total assets.

    Cash and Equivalents$68.68M
    Total Debt$0
    Net Cash$68.68M
    Net Cash Per Share$0.63
    Working Capital$1.63B
    Shareholder Equity$1.63B
    Book Value Per Share$15.00
    Total Assets$1.78B
    Total Liabilities$147.35M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $382.00K of capital spending, operating cash flow left -$202.28M of free cash flow.

    Operating Cash Flow-$201.90M
    Capital Expenditures$382.00K
    Free Cash Flow-$202.28M
    FCF Per Share-$1.86
    Depreciation and Amortization$7.94M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)+1.53%
    Tangible Book Per Share Growth (2Y CAGR)+1.53%

    Revenue and profit by year

    Dividends and Yields

    EWTX does not pay a dividend. Its free cash flow yield is -4.42%.

    FCF Yield-4.42%
    Buyback Yield-0.02%
    Shareholder Yield-0.02%

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About EWTX

    What is EWTX's market cap?

    Edgewise Therapeutics has a market cap of $5.03B. Its enterprise value, which adds debt and subtracts cash, is $4.96B.

    How many shares of EWTX are outstanding?

    Edgewise Therapeutics has 108.87M shares outstanding. The count is up 3.20% from a year earlier.

    Does EWTX pay a dividend?

    No. Edgewise Therapeutics does not pay a dividend.

    How much debt does EWTX have?

    Edgewise Therapeutics has $0 of total debt and $68.68M of cash and equivalents, a net cash position of $68.68M.